Sionna Therapeutics, Inc. $SION Shares Bought by TD Asset Management Inc

TD Asset Management Inc lifted its stake in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 74.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 87,082 shares of the company’s stock after acquiring an additional 37,116 shares during the period. TD Asset Management Inc’s holdings in Sionna Therapeutics were worth $2,561,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Goldman Sachs Group Inc. acquired a new position in Sionna Therapeutics during the first quarter worth approximately $667,000. Woodline Partners LP acquired a new position in shares of Sionna Therapeutics in the 1st quarter valued at $837,000. Geode Capital Management LLC grew its stake in shares of Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after buying an additional 153,712 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Sionna Therapeutics during the 2nd quarter valued at $45,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Sionna Therapeutics by 2.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock worth $38,538,000 after buying an additional 51,589 shares during the last quarter.

Insider Activity

In other news, Director Peter A. Thompson sold 33,356 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the completion of the sale, the director directly owned 3,561,655 shares in the company, valued at $158,671,730.25. This trade represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Orbimed Advisors Llc sold 33,356 shares of Sionna Therapeutics stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the sale, the director directly owned 3,561,655 shares in the company, valued at approximately $158,671,730.25. The trade was a 0.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 382,368 shares of company stock worth $15,898,607. 3.90% of the stock is currently owned by company insiders.

Sionna Therapeutics Price Performance

Shares of NASDAQ SION opened at $34.57 on Thursday. The company has a market capitalization of $1.56 billion and a price-to-earnings ratio of -17.73. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $45.00. The business has a 50-day moving average of $39.23 and a 200-day moving average of $35.31.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.15.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Royal Bank Of Canada reiterated an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a report on Monday, December 1st. BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday. Guggenheim lifted their price objective on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday. Raymond James Financial reissued a “strong-buy” rating and set a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. Finally, Citizens Jmp initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.57.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.